CABA Cabaletta Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CABA

Price (delayed)

$12.39

Market cap

$597.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.65

Enterprise value

$409.49M

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, ...

Highlights
The equity has soared by 126% YoY and by 47% from the previous quarter
CABA's EPS is up by 9% YoY and by 3.5% QoQ
Cabaletta Bio's quick ratio has increased by 34% YoY but it has decreased by 2.6% QoQ
CABA's debt is up by 18% since the previous quarter but it is down by 2.3% year-on-year
CABA's net income is down by 28% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cabalettabio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CABA
Market
Shares outstanding
48.24M
Market cap
$597.71M
Enterprise value
$409.49M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$67.68M
EBITDA
-$64.18M
Free cash flow
-$54.24M
Per share
EPS
-$1.65
Free cash flow per share
-$1.27
Book value per share
$5.51
Revenue per share
$0
TBVPS
$5.92
Balance sheet
Total assets
$253.65M
Total liabilities
$17.45M
Debt
$5.02M
Equity
$236.2M
Working capital
$228.5M
Liquidity
Debt to equity
0.02
Current ratio
15.29
Quick ratio
15.08
Net debt/EBITDA
2.93
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-37.9%
Return on equity
-40.8%
Return on invested capital
-171.2%
Return on capital employed
-28.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CABA stock price

How has the Cabaletta Bio stock price performed over time
Intraday
-1.67%
1 week
12.53%
1 month
-24.64%
1 year
1.23%
YTD
-45.42%
QTD
-27.37%

Financial performance

How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$74.66M
Net income
-$67.68M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 38% YoY and by 10% from the previous quarter
CABA's net income is down by 28% year-on-year and by 8% since the previous quarter

Growth

What is Cabaletta Bio's growth rate over time

Valuation

What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
2.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's EPS is up by 9% YoY and by 3.5% QoQ
The equity has soared by 126% YoY and by 47% from the previous quarter
CABA's price to book (P/B) is 32% lower than its last 4 quarters average of 3.3 but 7% higher than its 5-year quarterly average of 2.1

Efficiency

How efficient is Cabaletta Bio business performance
Cabaletta Bio's return on assets has increased by 24% YoY and by 12% QoQ
Cabaletta Bio's ROE has increased by 24% YoY and by 13% from the previous quarter
The ROIC has contracted by 22% YoY but it has grown by 4.3% from the previous quarter

Dividends

What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CABA.

Financial health

How did Cabaletta Bio financials performed over time
Cabaletta Bio's total assets has soared by 117% YoY and by 46% from the previous quarter
Cabaletta Bio's total liabilities has increased by 41% from the previous quarter and by 40% YoY
CABA's debt is 98% smaller than its equity
The equity has soared by 126% YoY and by 47% from the previous quarter
Cabaletta Bio's debt to equity has plunged by 60% YoY and by 33% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.